151 related articles for article (PubMed ID: 19789326)
1. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?
Ali M; Telfer BA; McCrudden C; O'Rourke M; Thomas HD; Kamjoo M; Kyle S; Robson T; Shaw C; Hirst DG; Curtin NJ; Williams KJ
Clin Cancer Res; 2009 Oct; 15(19):6106-12. PubMed ID: 19789326
[TBL] [Abstract][Full Text] [Related]
2. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
Calabrese CR; Almassy R; Barton S; Batey MA; Calvert AH; Canan-Koch S; Durkacz BW; Hostomsky Z; Kumpf RA; Kyle S; Li J; Maegley K; Newell DR; Notarianni E; Stratford IJ; Skalitzky D; Thomas HD; Wang LZ; Webber SE; Williams KJ; Curtin NJ
J Natl Cancer Inst; 2004 Jan; 96(1):56-67. PubMed ID: 14709739
[TBL] [Abstract][Full Text] [Related]
3. The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.
Ali M; Kamjoo M; Thomas HD; Kyle S; Pavlovska I; Babur M; Telfer BA; Curtin NJ; Williams KJ
Mol Cancer Ther; 2011 Dec; 10(12):2320-9. PubMed ID: 21926192
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
Daniel RA; Rozanska AL; Thomas HD; Mulligan EA; Drew Y; Castelbuono DJ; Hostomsky Z; Plummer ER; Boddy AV; Tweddle DA; Curtin NJ; Clifford SC
Clin Cancer Res; 2009 Feb; 15(4):1241-9. PubMed ID: 19174487
[TBL] [Abstract][Full Text] [Related]
5. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.
Thomas HD; Calabrese CR; Batey MA; Canan S; Hostomsky Z; Kyle S; Maegley KA; Newell DR; Skalitzky D; Wang LZ; Webber SE; Curtin NJ
Mol Cancer Ther; 2007 Mar; 6(3):945-56. PubMed ID: 17363489
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
Plummer R; Jones C; Middleton M; Wilson R; Evans J; Olsen A; Curtin N; Boddy A; McHugh P; Newell D; Harris A; Johnson P; Steinfeldt H; Dewji R; Wang D; Robson L; Calvert H
Clin Cancer Res; 2008 Dec; 14(23):7917-23. PubMed ID: 19047122
[TBL] [Abstract][Full Text] [Related]
7. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
Curtin NJ; Wang LZ; Yiakouvaki A; Kyle S; Arris CA; Canan-Koch S; Webber SE; Durkacz BW; Calvert HA; Hostomsky Z; Newell DR
Clin Cancer Res; 2004 Feb; 10(3):881-9. PubMed ID: 14871963
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.
Cheng CL; Johnson SP; Keir ST; Quinn JA; Ali-Osman F; Szabo C; Li H; Salzman AL; Dolan ME; Modrich P; Bigner DD; Friedman HS
Mol Cancer Ther; 2005 Sep; 4(9):1364-8. PubMed ID: 16170028
[TBL] [Abstract][Full Text] [Related]
9. Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.
McCrudden CM; O'Rourke MG; Cherry KE; Yuen HF; O'Rourke D; Babur M; Telfer BA; Thomas HD; Keane P; Nambirajan T; Hagan C; O'Sullivan JM; Shaw C; Williams KJ; Curtin NJ; Hirst DG; Robson T
PLoS One; 2015; 10(2):e0118187. PubMed ID: 25689628
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Plummer R; Lorigan P; Steven N; Scott L; Middleton MR; Wilson RH; Mulligan E; Curtin N; Wang D; Dewji R; Abbattista A; Gallo J; Calvert H
Cancer Chemother Pharmacol; 2013 May; 71(5):1191-9. PubMed ID: 23423489
[TBL] [Abstract][Full Text] [Related]
11. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
[TBL] [Abstract][Full Text] [Related]
12. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.
Miknyoczki S; Chang H; Grobelny J; Pritchard S; Worrell C; McGann N; Ator M; Husten J; Deibold J; Hudkins R; Zulli A; Parchment R; Ruggeri B
Mol Cancer Ther; 2007 Aug; 6(8):2290-302. PubMed ID: 17699724
[TBL] [Abstract][Full Text] [Related]
13. Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.
Vazquez-Ortiz G; Chisholm C; Xu X; Lahusen TJ; Li C; Sakamuru S; Huang R; Thomas CJ; Xia M; Deng C
Breast Cancer Res; 2014 Jun; 16(3):R67. PubMed ID: 24962108
[TBL] [Abstract][Full Text] [Related]
14. INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.
Sun Y; Ding H; Liu X; Li X; Li L
Tumour Biol; 2014 May; 35(5):4469-77. PubMed ID: 24420152
[TBL] [Abstract][Full Text] [Related]
15. [Effects of poly(ADP-ribose)polymerase inhibitor AG014699 combined with chemotherapy on the proliferation of triple-negative breast cancer cell line MDA-MB-231].
Sun Y; Ding H; Li XQ; Li L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2014 Apr; 36(2):135-9. PubMed ID: 24791791
[TBL] [Abstract][Full Text] [Related]
16. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.
Daniel RA; Rozanska AL; Mulligan EA; Drew Y; Thomas HD; Castelbuono DJ; Hostomsky Z; Plummer ER; Tweddle DA; Boddy AV; Clifford SC; Curtin NJ
Br J Cancer; 2010 Nov; 103(10):1588-96. PubMed ID: 20978505
[TBL] [Abstract][Full Text] [Related]
18. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B
Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281
[TBL] [Abstract][Full Text] [Related]
19. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
Donawho CK; Luo Y; Luo Y; Penning TD; Bauch JL; Bouska JJ; Bontcheva-Diaz VD; Cox BF; DeWeese TL; Dillehay LE; Ferguson DC; Ghoreishi-Haack NS; Grimm DR; Guan R; Han EK; Holley-Shanks RR; Hristov B; Idler KB; Jarvis K; Johnson EF; Kleinberg LR; Klinghofer V; Lasko LM; Liu X; Marsh KC; McGonigal TP; Meulbroek JA; Olson AM; Palma JP; Rodriguez LE; Shi Y; Stavropoulos JA; Tsurutani AC; Zhu GD; Rosenberg SH; Giranda VL; Frost DJ
Clin Cancer Res; 2007 May; 13(9):2728-37. PubMed ID: 17473206
[TBL] [Abstract][Full Text] [Related]
20. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
